661 research outputs found
Alien Registration- Philippon, Marie B. (Portland, Cumberland County)
https://digitalmaine.com/alien_docs/21315/thumbnail.jp
Diabete Aftricain en France
Introduction :
Les auteurs rapportent le cas dâun diabĂšte africain ou diabĂšte atypique dĂ©signe un type spĂ©cifique de diabĂšte prĂ©sentant au dĂ©part des stigmates dâun diabĂšte de type 1 mais dont lâĂ©volution ultĂ©rieure se fait vers un diabĂšte de type 2 avec la possibilitĂ© dâune longue phase de rĂ©mission. Il sâagit dâun sujet dâorigine africaine, des spĂ©cificitĂ©s diagnostiques, mĂ©taboliques, physiopathologiques et prise en charge de ce type de diabĂšte. Patients et mĂ©thodes : Il sâagit dâune observation clinique dâun patient dâorigine africaine vivant en France ayant un diabĂšte atypique. Cas clinique : Patient ĂągĂ© de 33 ans, a Ă©tĂ© hospitalisĂ© pour une acidocĂ©tose diabĂ©tique. Il a un antĂ©cĂ©dent familial de diabĂšte de type 2, un surpoids (IMC = 28,73 Kg/m2). Une insulinothĂ©rapie a Ă©tĂ© instaurĂ©e. Le bilan Ă©tiologique de cette dĂ©compensation mĂ©tabolique et la recherche de dâanticorps anti-GAD et anti-IA2 sont nĂ©gatifs. AprĂšs 3 mois dâinsulinothĂ©rapie, on obtient un Ă©quilibre glycĂ©mique satisfaisant marquĂ© par une HbA1c Ă 7 % et un peptide C remontĂ© Ă 300 pmol/l (pour une GV Ă 1,09g/l). Au 6Ăšme mois, le patient prĂ©sente un parfait Ă©quilibre glycĂ©mique (HbA1C : 6,4 %), avec un peptide C qui sâest normalisĂ© Ă 870 pmol/l (pour une GV Ă 1,29g/l). Câest ce qui a permis de proposer lâarrĂȘt de lâinsulinothĂ©rapie. Pour des raisons sociales, le patient refuse lâarrĂȘt du traitement. Aucune anomalie nâa Ă©tĂ© objectivĂ©e au fond dâĆil, ni Ă lâĂ©lectrocardiogramme, ni Ă lâĂ©valuation de la fonction rĂ©nale (Clairance de crĂ©atinine normale par MDRD et micro-albuminurie nĂ©gative). Ce tableau clinique illustre un cas de diabĂšte dâun africain. Il sâagit dâune expression clinique proche du diabĂšte de type 1 (DT1) mais se caractĂ©rise par une rĂ©mission, plus lente que la lune de miel dans le DT1, avec une absence de stigmates dâauto-immunitĂ©. Il est considĂ©rĂ© comme diabĂšte atypique ou de type 1 idiopathique. Conclusion : Ce type de diabĂšte Ă©voque plusieurs hypothĂšses physiopathologiques. LâĂ©quilibre glycĂ©mique est rapidement obtenu sous insulinothĂ©rapie, avec possibilitĂ© de rĂ©Ă©mission
Introduction : The authors report the case of African diabetes or atypical diabetes refers to a specific type of diabetes presenting initially with the stigma of type 1 diabetes but whose subsequent evolution is towards type 2 diabetes with the possibility of a long remission phase. This is a subject of African origin, and the diagnostic, metabolic, pathophysiological, and management specificities of this type of diabetes. Patients and methods: This is a clinical observation of a patient of African origin living in France with atypical diabetes. Clinical case: A 33-year-old patient was hospitalized for diabetic ketoacidosis. He had a family history of type 2 diabetes and was overweight (BMI = 28.73 kg/m2). Insulin therapy was initiated. The aetiological assessment of this metabolic decompensation and the search for anti-GAD and anti-IA2 antibodies were negative. After 3 months of insulin therapy, a satisfactory glycaemic balance was obtained, marked by an HbA1c of 7% and a C-peptide of 300 pmol/l (for a GV of 1.09g/l). At the 6th month, the patient had perfect glycaemic control (HbA1C: 6.4%), with a C-peptide that had normalized to 870 pmol/l (for a GV of 1.29g/l). This was the basis for proposing the discontinuation of insulin therapy. For social reasons, the patient refused to stop the treatment. No abnormalities were observed on the fundus, electrocardiogram, or renal function tests (normal creatinine clearance by MDRD and negative microalbuminuria). This clinical picture illustrates a case of diabetes in an African. It is a clinical expression close to type 1 diabetes (T1DM) but is characterized by remission, slower than the honeymoon period in T1DM, with an absence of autoimmune stigma. It is considered atypical or idiopathic type 1 diabetes. Conclusion: This type of diabetes raises several pathophysiological hypotheses. Glycaemic control is rapidly achieved with insulin therapy, with the possibility of re-emissio
Diabete African en France
Introduction: Le diabĂšte africain ou diabĂšte atypique dĂ©signe un type spĂ©cifique de diabĂšte prĂ©sentant au dĂ©part des stigmates dâun diabĂšte de type 1 mais dont lâĂ©volution ultĂ©rieure se fait vers un diabĂšte de type 2 avec la possibilitĂ© dâune longue phase de rĂ©mission. Nous discuterons dans cet article a travers un cas clinique chez un sujet dâorigine africaine, des spĂ©cificitĂ©s diagnostiques, mĂ©taboliques, physiopathologiques et prise en charge de ce type de diabĂšte. Patients et mĂ©thodes : Il sâagit dâune observation clinique particuliĂšre dâun patient dâorigine africaine vivant en France ayant un diabĂšte atypique. Cas clinique : Patient, ĂągĂ©e de 33 ans, a Ă©tĂ© hospitalisĂ© pour une acidocĂ©tose diabĂ©tique. Il a une hĂ©rĂ©ditĂ© familiale de diabĂšte de type 2, un surpoids (IMC = 28,73 Kg/m2). Une insulinothĂ©rapie a Ă©tĂ© instaurĂ©e. Le bilan Ă©tiologique de cette dĂ©compensation mĂ©tabolique et la recherche de dâanticorps anti-GAD et anti-IA2 sont nĂ©gatifs. AprĂšs 3 mois dâinsulinothĂ©rapie, on obtient un Ă©quilibre glycĂ©mique satisfaisant marquĂ© par une HbA1c Ă 7 % et un peptide C remontĂ© Ă 300 pmol/l (pour une GV Ă 1,09g/l). Au bilan du 6 mois, le patient prĂ©sente un parfait Ă©quilibre glycĂ©mique (HbA1C : 6,4 %), avec un peptide C qui sâest normalisĂ© Ă 870 pmol/l (pour une GV Ă 1,29g/l). Câest qui a permis de proposer lâarrĂȘt de lâinsulinothĂ©rapie malheureusement rĂ©cusĂ© par le patient pour des raisons sociales. Aucune anomalie nâa Ă©tĂ© objectivĂ©e au fond de lâĆil, ni Ă lâĂ©lectro-cardiogramme, ni Ă lâĂ©valuation de la fonction rĂ©nale (Clairance de crĂ©atinine normale par MDRD et micro-albuminurie nĂ©gative). Ce tableau clinique illustre un cas de diabĂšte africain. Il sâagit dâune expression clinique proche du diabĂšte de type 1 (DT1) mais se caractĂ©rise par une rĂ©mission, plus lente que la lune de miel dans le DT1, avec une absence de stigmates dâauto-immunitĂ©. Il est considĂ©rĂ© comme diabĂšte atypique ou de type 1 idiopathique. Discussion /Conclusion : Ce type de diabĂšte Ă©voque plusieurs hypothĂšses physiopathologiques. LâĂ©quilibre glycĂ©mique est rapidement obtenu sous insulinothĂ©rapie, avec possibilitĂ© de rĂ©Ă©mission.
African diabetes or atypical diabetes refers to a specific type of diabetes that initially presents with the stigma of type 1 diabetes but later progresses to type 2 diabetes with the possibility of a long remission phase.
We will discuss in this article, through a clinical case in a subject of African origin, the diagnostic, metabolic, physiopathological and management specificities of this type of diabetes. Patients and methods: This is a particular clinical observation of a patient of African origin living in France with atypical diabetes. Clinical case: Patient, aged 33 years, was hospitalized for diabetic ketoacidosis. He had a family history of type 2 diabetes, was overweight (BMI = 28.73 Kg/m2). Insulin therapy was initiated. The etiological assessment of this metabolic decompensation and the search for anti-GAD and anti-IA2 antibodies were negative. After 3 months of insulin therapy, a satisfactory glycemic balance was obtained, marked by an HbA1c of 7% and a C-peptide of 300 pmol/l (for a GV of 1.09 g/l). At the 6-month check-up, the patient had perfect glycemic control (HbA1C: 6.4%), with a C-peptide that had normalized to 870 pmol/l (for a GV of 1.29g/l). This was the reason for proposing the discontinuation of insulin therapy, which was unfortunately rejected by the patient for social reasons. No abnormality was observed on the fundus, electrocardiogram or renal function tests (normal creatinine clearance by MDRD and negative microalbuminuria). This clinical picture illustrates a case of African diabetes. It is a clinical expression close to type 1 diabetes (T1DM) but is characterized by a remission, slower than the honeymoon in T1DM, with an absence of autoimmune stigma. It is considered atypical or idiopathic type 1 diabetes. Discussion/Conclusion : This type of diabetes raises several pathophysiological hypotheses. Glycemic control is rapidly obtained with insulin therapy, with the possibility of re-emission
Diabete African en France
Introduction: Le diabĂšte africain ou diabĂšte atypique dĂ©signe un type spĂ©cifique de diabĂšte prĂ©sentant au dĂ©part des stigmates dâun diabĂšte de type 1 mais dont lâĂ©volution ultĂ©rieure se fait vers un diabĂšte de type 2 avec la possibilitĂ© dâune longue phase de rĂ©mission. Nous discuterons dans cet article a travers un cas clinique chez un sujet dâorigine africaine, des spĂ©cificitĂ©s diagnostiques, mĂ©taboliques, physiopathologiques et prise en charge de ce type de diabĂšte. Patients et mĂ©thodes : Il sâagit dâune observation clinique particuliĂšre dâun patient dâorigine africaine vivant en France ayant un diabĂšte atypique. Cas clinique : Patient, ĂągĂ©e de 33 ans, a Ă©tĂ© hospitalisĂ© pour une acidocĂ©tose diabĂ©tique. Il a une hĂ©rĂ©ditĂ© familiale de diabĂšte de type 2, un surpoids (IMC = 28,73 Kg/m2). Une insulinothĂ©rapie a Ă©tĂ© instaurĂ©e. Le bilan Ă©tiologique de cette dĂ©compensation mĂ©tabolique et la recherche de dâanticorps anti-GAD et anti-IA2 sont nĂ©gatifs. AprĂšs 3 mois dâinsulinothĂ©rapie, on obtient un Ă©quilibre glycĂ©mique satisfaisant marquĂ© par une HbA1c Ă 7 % et un peptide C remontĂ© Ă 300 pmol/l (pour une GV Ă 1,09g/l). Au bilan du 6 mois, le patient prĂ©sente un parfait Ă©quilibre glycĂ©mique (HbA1C : 6,4 %), avec un peptide C qui sâest normalisĂ© Ă 870 pmol/l (pour une GV Ă 1,29g/l). Câest qui a permis de proposer lâarrĂȘt de lâinsulinothĂ©rapie malheureusement rĂ©cusĂ© par le patient pour des raisons sociales. Aucune anomalie nâa Ă©tĂ© objectivĂ©e au fond de lâĆil, ni Ă lâĂ©lectro-cardiogramme, ni Ă lâĂ©valuation de la fonction rĂ©nale (Clairance de crĂ©atinine normale par MDRD et micro-albuminurie nĂ©gative). Ce tableau clinique illustre un cas de diabĂšte africain. Il sâagit dâune expression clinique proche du diabĂšte de type 1 (DT1) mais se caractĂ©rise par une rĂ©mission, plus lente que la lune de miel dans le DT1, avec une absence de stigmates dâauto-immunitĂ©. Il est considĂ©rĂ© comme diabĂšte atypique ou de type 1 idiopathique. Discussion /Conclusion : Ce type de diabĂšte Ă©voque plusieurs hypothĂšses physiopathologiques. LâĂ©quilibre glycĂ©mique est rapidement obtenu sous insulinothĂ©rapie, avec possibilitĂ© de rĂ©Ă©mission.
African diabetes or atypical diabetes refers to a specific type of diabetes that initially presents with the stigma of type 1 diabetes but later progresses to type 2 diabetes with the possibility of a long remission phase.
We will discuss in this article, through a clinical case in a subject of African origin, the diagnostic, metabolic, physiopathological and management specificities of this type of diabetes. Patients and methods: This is a particular clinical observation of a patient of African origin living in France with atypical diabetes. Clinical case: Patient, aged 33 years, was hospitalized for diabetic ketoacidosis. He had a family history of type 2 diabetes, was overweight (BMI = 28.73 Kg/m2). Insulin therapy was initiated. The etiological assessment of this metabolic decompensation and the search for anti-GAD and anti-IA2 antibodies were negative. After 3 months of insulin therapy, a satisfactory glycemic balance was obtained, marked by an HbA1c of 7% and a C-peptide of 300 pmol/l (for a GV of 1.09 g/l). At the 6-month check-up, the patient had perfect glycemic control (HbA1C: 6.4%), with a C-peptide that had normalized to 870 pmol/l (for a GV of 1.29g/l). This was the reason for proposing the discontinuation of insulin therapy, which was unfortunately rejected by the patient for social reasons. No abnormality was observed on the fundus, electrocardiogram or renal function tests (normal creatinine clearance by MDRD and negative microalbuminuria). This clinical picture illustrates a case of African diabetes. It is a clinical expression close to type 1 diabetes (T1DM) but is characterized by a remission, slower than the honeymoon in T1DM, with an absence of autoimmune stigma. It is considered atypical or idiopathic type 1 diabetes. Discussion/Conclusion : This type of diabetes raises several pathophysiological hypotheses. Glycemic control is rapidly obtained with insulin therapy, with the possibility of re-emission
The relationship between the Sahelian and previous 2nd Guinean rainy seasons: a monsoon regulation by soil wetness?
Patient-Reported Outcome questionnaires for hip arthroscopy: a systematic review of the psychometric evidence
Abstract Background Hip arthroscopies are often used in the treatment of intra-articular hip injuries. Patient-reported outcomes (PRO) are an important parameter in evaluating treatment. It is unclear which PRO questionnaires are specifically available for hip arthroscopy patients. The aim of this systematic review was to investigate which PRO questionnaires are valid and reliable in the evaluation of patients undergoing hip arthroscopy. Methods A search was conducted in Pubmed, Medline, CINAHL, the Cochrane Library, Pedro, EMBASE and Web of Science from 1931 to October 2010. Studies assessing the quality of PRO questionnaires in the evaluation of patients undergoing hip arthroscopy were included. The quality of the questionnaires was evaluated by the psychometric properties of the outcome measures. The quality of the articles investigating the questionnaires was assessed by the COSMIN list. Results Five articles identified three questionnaires; the Modified Harris Hip Score (MHHS), the Nonarthritic Hip Score (NAHS) and the Hip Outcome Score (HOS). The NAHS scored best on the content validity, whereas the HOS scored best on agreement, internal consistency, reliability and responsiveness. The quality of the articles describing the HOS scored highest. The NAHS is the best quality questionnaire. The articles describing the HOS are the best quality articles. Conclusions This systematic review shows that there is no conclusive evidence for the use of a single patient-reported outcome questionnaire in the evaluation of patients undergoing hip arthroscopy. Based on available psychometric evidence we recommend using a combination of the NAHS and the HOS for patients undergoing hip arthroscopy.</p
Genetic Relations Between the Aves Ridge and the Grenada Back-Arc Basin, East Caribbean Sea
The Grenada Basin separates the active Lesser Antilles Arc from the Aves Ridge, described as a CretaceousâPaleocene remnant of the âGreat Arc of the Caribbean.â Although various tectonic models have been proposed for the opening of the Grenada Basin, the data on which they rely are insufficient to reach definitive conclusions. This study presents, a large set of deepâpenetrating multichannel seismic reflection data and dredge samples acquired during the GARANTI cruise in 2017. By combining them with published data including seismic reflection data, wideâangle seismic data, well data and dredges, we refine the understanding of the basement structure, depositional history, tectonic deformation and vertical motions of the Grenada Basin and its margins as follows: (1) rifting occurred during the late Paleoceneâearly Eocene in a NWâSE direction and led to seafloor spreading during the middle Eocene; (2) this newly formed oceanic crust now extends across the eastern Grenada Basin between the latitude of Grenada and Martinique; (3) asymmetrical preâMiocene depocenters support the hypothesis that the southern Grenada Basin originally extended beneath the presentâday southern Lesser Antilles Arc and probably partly into the presentâday forearc before the late OligoceneâMiocene rise of the Lesser Antilles Arc; and (4) the Aves Ridge has subsided along with the Grenada Basin since at least the middle Eocene, with a general subsidence slowdown or even an uplift during the late Oligocene, and a sharp acceleration on its southeastern flank during the late Miocene. Until this acceleration of subsidence, several bathymetric highs remained shallow enough to develop carbonate platforms
- âŠ